US firms establish strategic partnership around biosimilars

Privately-held Oncobiologics has formed a broad strategic partnership with fellow USA-based inVentiv Health around clinical development for all assets in Oncobiologic's pipeline. The scope of the partnership is global and will initially focus on biosimilar assets, and could be expanded to include innovative molecules.

Through the partnership, inVentiv Health will provide leadership and execution for clinical studies, as well as the corresponding bioanalytical support for those trials. As the assets are commercialized, the partnership will be broadened to include inVentiv's significant commercialization capabilities in select countries. This will position Oncobiologics attractively in seeking future commercial partners.

Seek to copy five drugs with combined sales of over $40 billion